SPECULATING IN TAKEOVER TARGETS Message Board

Sponsor

From: richardred	4/23/2012 9:33:07 AM
	of 3402

Ardea soars on takeover dealDeal Would Add Late-Stage Compound Ardea Biosciences agreed to be acquired by AstraZeneca for $32 a share. The company's most advanced product compound, Lesinurad, is currently in Phase III development as a potential treatment for the chronic management of hyperuricaemia in patients with gout. RDEA is up 51 percent in the premarket. ConocoPhillips reported first-quarter earnings of $2.02 a share. Analysts had expected $2.08 average analyst forecast, and COP is down more than 2 percent before the bell. Kellogg Lowers Guidance Kellogg expects full-year earnings of $3.18 to $3.30 a share, down from an earlier forecast of $3.44 to $3.51. Management blamed weak first-quarter results, slowness in Europe and stagnation in certain U.S. categories. K is down 6 percent in premarket trade on my tradeMONSTER platform. Amylin Seeks a Buyer Amylin Pharmaceuticals has hired Credit Suisse and Goldman Sachs to help find a buyer. The company had turned down a takeover off from Bristol-Myers Squibb earlier in the year. AMLN rose 11 percent before the bell. finance.yahoo.com